NYSE:PRGO - Perrigo Stock Price, Price Target & More

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo declared a quarterly dividend on Thursday, May 3rd. Stockholders of record on Friday, June 1st will be given a dividend of $0.19 per share on Tuesday, June 19th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date is Thursday, May 31st. View Perrigo's Dividend History.

Perrigo Company PLC (NYSE:PRGO) announced its quarterly earnings results on Tuesday, May, 8th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.14 by $0.12. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.21 billion. Perrigo had a net margin of 2.59% and a return on equity of 11.93%. The business's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.05 EPS. View Perrigo's Earnings History.

Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Perrigo.

Perrigo issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $5.05-5.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.26.

17 Wall Street analysts have issued twelve-month price objectives for Perrigo's stock. Their forecasts range from $79.00 to $117.00. On average, they anticipate Perrigo's stock price to reach $93.6875 in the next twelve months. View Analyst Ratings for Perrigo.

Some companies that are related to Perrigo include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY) and Jazz Pharmaceuticals (JAZZ).

Headlines about PRGO stock have been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Perrigo earned a news impact score of 0.10 on Accern's scale. They also gave media coverage about the company an impact score of 44.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Perrigo's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.17%), Franklin Resources Inc. (5.86%), Victory Capital Management Inc. (1.75%), Clal Insurance Enterprises Holdings Ltd (1.39%), Manning & Napier Group LLC (1.23%) and Millennium Management LLC (1.02%). Company insiders that own Perrigo stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Judy L Brown, Sharon Kochan, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.

PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Migdal Insurance & Financial Holdings Ltd., Sector Gamma AS, Swiss National Bank, Millennium Management LLC, UBS Group AG, Quadrature Capital Ltd and Engineers Gate Manager LP. Company insiders that have sold Perrigo company stock in the last year include Jeffrey Needham, John Wesolowski, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Insider Buying and Selling for Perrigo.

PRGO stock was acquired by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, Clal Insurance Enterprises Holdings Ltd, Victory Capital Management Inc., New York State Common Retirement Fund, Point72 Asset Management L.P., Franklin Resources Inc., Prudential Financial Inc. and Dimensional Fund Advisors LP. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRGO stock can currently be purchased for approximately $75.64.

Perrigo has a market capitalization of $10.40 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe.

Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]